These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

781 related articles for article (PubMed ID: 27533061)

  • 21. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
    Noel ZR; Beavers CJ
    Am J Med; 2017 Feb; 130(2):229.e1-229.e4. PubMed ID: 27751895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
    Dijk W; Cariou B
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():39-51. PubMed ID: 31002456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives.
    Fitzgerald G; Kiernan T
    Expert Rev Cardiovasc Ther; 2018 Aug; 16(8):567-578. PubMed ID: 29979908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
    Ortega Martínez de Victoria E
    Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
    [No Abstract]   [Full Text] [Related]  

  • 26. New Drugs for Lowering LDL-Cholesterol.
    Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.
    Zheng-Lin B; Ortiz A
    Drugs; 2018 Feb; 78(2):215-229. PubMed ID: 29299849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Inhibitors of PCSK9].
    Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
    Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
    Katsiki N; Athyros VG; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Sep; 74():43-46. PubMed ID: 28477848
    [No Abstract]   [Full Text] [Related]  

  • 30. [PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].
    Thiery J; Burkhardt R
    Herz; 2016 Jun; 41(4):281-9. PubMed ID: 27215417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
    Shimada YJ; Cannon CP
    Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proprotein convertase subtilisin/kexin type 9 in kidney disease.
    Schmit D; Fliser D; Speer T
    Nephrol Dial Transplant; 2019 Aug; 34(8):1266-1271. PubMed ID: 31190079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol.
    Whayne TF
    Drugs; 2018 Mar; 78(3):287-291. PubMed ID: 29396831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined lipid-lowering therapy.
    Karásek D
    Vnitr Lek; 2019; 64(12):1177-1184. PubMed ID: 30704254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A; Demir K; Altunkeser BB
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.